Glybochko P V, Alekseenko S N, Gubareva E A, Kuevda E V, Basov A A, Sotnichenko A S, Dzhimak S S, Gumenyuk I S, Egiev I Kh, Chechelyan V N, Nakokhov R Z, Lyasota O M, Teterin Yu V
I.M. Sechenov First Moscow State Medical University, Ministry of Health of the Russian Federation, Moscow, Russia.
Kuban State Medical University of Minzdrav of Russia, Krasnodar, Russia.
Urologiia. 2017 Jun(2):5-13. doi: 10.18565/urol.2017.2.5-13.
Chronic renal failure (CRF) is one of the most challenging problems of contemporary medicine. Patients with chronic renal failure usually need renal replacement therapy as either hemodialysis, peritoneal dialysis or a kidney transplant. The latter is the most promising option for end-stage kidney disease. However, the shortage of donor organs, the complexity of their delivery, the difficulty in finding an immunologically compatible donor and the need for lifelong immunosuppression triggered advances in modern tissue engineering. In this field, the primary priority is focused on developing bioengineered scaffolds with subsequent recellularization with autologous cells. Using such constructs would allow for solving both ethical and immunological problems of transplantation. The aim of this pilot study was to develop a new method of renal decellularization using small laboratory animals.
The study investigated the morphological structure of the obtained decellularized matrix and quantitatively tested DNA residues in the resulting scaffold. We proposed a new biophysical method for assessing the matrix quality using the EPR spectroscopy and conducted experiments on the matrix recellularization with mesenchymal multipotent stem cells to estimate cytotoxicity, cell viability and metabolic activity.
The obtained decellularized renal matrix retained the native tissue architecture after a complete removal of the cell material, had no cytotoxic properties and supported cell adhesion and proliferation.
All the above suggests that the proposed decellularization protocol is a promising method to produce tissue-engineered kidney constructs with possible clinical application in the foreseeable future.
慢性肾衰竭(CRF)是当代医学最具挑战性的问题之一。慢性肾衰竭患者通常需要肾脏替代治疗,如血液透析、腹膜透析或肾移植。后者是终末期肾病最有前景的选择。然而,供体器官短缺、器官输送的复杂性、寻找免疫相容性供体的困难以及终身免疫抑制的需求推动了现代组织工程学的发展。在这个领域,首要重点是开发生物工程支架,并随后用自体细胞进行再细胞化。使用这样的构建体将能够解决移植的伦理和免疫问题。这项初步研究的目的是开发一种使用小型实验动物进行肾脏去细胞化的新方法。
该研究调查了所获得的去细胞化基质的形态结构,并对所得支架中的DNA残留进行了定量检测。我们提出了一种使用电子顺磁共振光谱评估基质质量的新生物物理方法,并对间充质多能干细胞进行基质再细胞化实验,以评估细胞毒性、细胞活力和代谢活性。
所获得的去细胞化肾脏基质在完全去除细胞物质后保留了天然组织结构,没有细胞毒性特性,并支持细胞黏附和增殖。
上述所有结果表明,所提出的去细胞化方案是一种有前景的方法,可用于生产组织工程肾脏构建体,在可预见的未来可能具有临床应用价值。